Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06849973 · ClinicalTrials.gov registry record · Phase 2

To Study the Efficacy & Safety of Oral NA-921 (Bionetide) in Girls and Women with Rett Syndrome

A Phase 2 study of Rett Syndrome, sponsored by Biomed Industries.

Completed
Registry status
Phase 2
Development phase
187
Enrollment target
16
Study locations

NCT06849973 is a Phase 2 study of Rett Syndrome that has completed, run by Biomed Industries. The registered enrollment target is 187 participants, below the 515-participant average among 18 other Rett Syndrome trials with a reported enrollment target (64% lower). The trial reports 16 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06849973, a Phase 2 study of Rett Syndrome, has completed, sponsored by Biomed Industries.

COMPLETED
Registry status
Phase 2
Development phase
187 participants
Enrollment target
16
Study locations

Study Summary

To study the efficacy \& safety of oral Bionetide versus placebo in girls and women with Rett syndrome

Conditions Studied

Rett Syndrome

Interventions

  • DRUG Placebo
  • DRUG Drug: Bionetide

Study Locations (16)

California

  • Biomed Testing Facility # BIO-04-92093 - La Jolla
  • Biomed Testing Facility # BIO-03-90095 - Los Angeles
  • Biomed Testing Facility # BIO-02-95817 - Sacramento
  • Biomed Testing Facility # BIO-01-94104 - San Francisco

New South Wales

  • Biomed Research Unit-BIO-16-NSW - Camperdown
  • Biomed Research Unit-BIO-15 - Sydney

Victoria

  • Biomed Research Unit-BIO-13-VIC-3084 Heidelberg West, Victoria, Australia, 3084 - Heidelberg West
  • Biomed Research Unit- BIO-14-VIC 3010 - Parkville

Colorado

  • Biomed Testing Facility #BIO-05-80042 - Aurora

Illinois

  • Biomed Testing Facility #BIO-06-60612 - Chicago

Maryland

  • Maryland Locations Biomed Testing Facility #BIO-7-21205 - Baltimore

Massachusetts

  • Biomed Testing Facility #BIO-8-02115 - Boston

New York

  • Biomed Testing Facility #BIO-9-10467 - The Bronx

Trial Details

FieldValue
Enrollment Target 187 participants
Start Date 2024-03-15
Est. Completion 2025-01-28
Phase Phase 2

Sponsor

Biomed Industries

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06849973

The ClinicalTrials.gov registry entry for NCT06849973 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 187 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 515-participant average among 18 other Rett Syndrome trials with a reported enrollment target (64% lower). The listed sponsor is Biomed Industries, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rett Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06849973 reports 16 study locations spanning 11 distinct geographic areas - top geographies include California, New South Wales, Victoria.

Frequently Asked Questions

What is clinical trial NCT06849973 about?

NCT06849973 is a clinical study titled "To Study the Efficacy & Safety of Oral NA-921 (Bionetide) in Girls and Women with Rett Syndrome". To study the efficacy \& safety of oral Bionetide versus placebo in girls and women with Rett syndrome

What is the current status of trial NCT06849973?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 187 participants. The study started on 2024-03-15. Estimated completion is 2025-01-28.

What conditions does trial NCT06849973 study?

This clinical trial studies the following conditions: Rett Syndrome.

What interventions are being tested in trial NCT06849973?

The interventions under investigation include: Placebo (DRUG), Drug: Bionetide (DRUG).

Who is sponsoring clinical trial NCT06849973?

This trial is sponsored by Biomed Industries, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06849973 being conducted?

This trial has 16 study locations across California, Colorado, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rett Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Rett Syndrome

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.